Navigation Links
Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
Date:7/30/2008

cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving future products and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2007 and Anadys' most recent Form 10-Q. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Condensed Consolidated Financial Statements

Anadys Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(In thousands except per share amounts)

(Unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

Revenues $ - $ 1,302 $ - $2,404

Operating expenses

Research and

development (1) 5,501 6,975 11,510 13,673

General and


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
5. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
6. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
7. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
8. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
9. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
10. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Selexis SA, a serial innovation company ... (RCBs) used for drug discovery to commercial manufacturing, announced ... Next-Generation Sequencing (NGS) data packages. The NGS ... by ensuring the integrity of the gene, validation of ...
(Date:1/22/2015)... Calif. , Jan. 22. 2015  Varian Medical Systems (NYSE: ... software, has been honored for its commitment to sustainability with ... companies. Varian is the highest ranked healthcare equipment company among ... today during the World Economic Forum at Davos, ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 “Preparative ... Gas, HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, ... Food & Agriculture) - Forecasts to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
... (Nasdaq: RGEN ) announced today that the Company ... present at the Cowen and Company 29th Annual Healthcare Conference ... the Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA. ... via Repligen,s website at www.repligen.com and will be ...
... Human Genome Sciences, Inc. (Nasdaq: ... a conference call to discuss the results of its ... in patients with genotype 1 chronic hepatitis C.(Logo: ... senior management and will be held on Monday, March ...
... - Attendees at The 18th CPM ... Plan Era , The healthcare ... of,the billions allotted for healthcare information technology transformation in,the ... "Stimulus,Package," according to observations shared at the 18th CPM ...
Cached Biology Technology:Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT 2Human Genome Sciences to Sponsor Conference Call 2Experts at Healthcare Conference Support Investments in the Health of Work Culture and Care Processes, Not Just Technology 2Experts at Healthcare Conference Support Investments in the Health of Work Culture and Care Processes, Not Just Technology 3Experts at Healthcare Conference Support Investments in the Health of Work Culture and Care Processes, Not Just Technology 4
(Date:12/17/2014)... The Defense Logistics Agency is insourcing its efforts ... microcircuits from entering into its supply chain. ... initiative dubbed DNA marking. The capability will validate the ... the supply chain. The new quality control measures will ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience and nowhere ... the past decade, ePassports, biometric readers, and secure document ... border control via eGates and Automated Passport Control (APC) ... land borders across the globe. According ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... the U.K. says doctors, authors and educators are doing ... we understand it today has always existed. Matthew ... misleads patients, their parents and their physicians. Smith, ... at the Centre for Medical History at the University ...
... DC -- It,s called a "Dream Team." ... Craig Jordan, OBE, PhD, DSc, and 12 of the ... multi-million dollar grant from Stand Up To Cancer (SU2C) ... collaboration of the best and brightest scientists will conduct ...
... The Society of Environmental Toxicology and Chemistry will host ... theme of "Protecting Ecosystem Health: Facing the Challenge of ... at the Gothenburg Convention Centre, Sweden. Nanotechnology,s ... of contaminants at the molecular level, polar ecotoxicology, and ...
Cached Biology News:History of hyperactivity off-base, says researcher 2Lombardi scientist brings 'dream team' breast cancer research effort to GUMC 2Lombardi scientist brings 'dream team' breast cancer research effort to GUMC 3SETAC Europe addresses global ecosystem health in Gothenburg 2
...
... OrientExpress™ System Modules ... synthesis and directional cloning ... T7 expression vectors ... configuring OrientExpress™ Cloning Systems, ...
... While antigen and antibody-based immunoaffinity matrices, ... reused many times without compromising antigen-antibody ... and chaotropic agents has precluded the ... blotting. The CHEMICON Re-Blot Plus ...
Applications: Western blotting ...
Biology Products: